GlaxoSmithKline Pharmaceuticals Limited has announced its financial results for the second quarter ended 30th June 2011. While the net Sales grew by 13%, Sales of the core Pharmaceuticals and vaccines business grew by 14%. Profit After tax (before Exceptionals) grew by 9% during the quarter, and the Operating Profit margin was maintained at 35% in line with the first quarter of 2011. Planned investments in field force expansion for the year continued during the quarter.

Commenting on the performance during the quarter, Dr. Hasit B. Joshipura, Managing Director, said, “The Company’s growth has been in line with the market growth. In particular, Oncology, Dermatologicals and Mass Specialty therapies have grown well. In addition to the base effect, vaccines has shown strong market competitive growth.”

Apart from two original products from the GSK pipeline in Oncology and Haematology, a branded generic and a product in Stiefel –Dermatology was launched during the quarter.

About GlaxoSmithKline:

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GlaxoSmithKline plc, one of the world's leading research-based pharmaceutical and healthcare companies, committed to improving the quality of human life by enabling people to do more, feel better and live longer.

For more information, visit www.gsk-india.com.

For enquires, please contact:

Sunder Rajan
General Manager – Corporate Communications

+91 22 24959203
sunder.r.raj@gsk.com